Myeloma cell therapies, now in pharma hands, move into spotlight

Myeloma cell therapies, now in pharma hands, move into spotlight

Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival

Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival

CAR-T Therapy Development on the Rise

CAR-T Therapy Development on the Rise

Sanofi to Develop Biomunex Bi-, Multi-Specific Antibodies for Immuno-Oncology and Other Areas

Sanofi to Develop Biomunex Bi-, Multi-Specific Antibodies for Immuno-Oncology and Other Areas

The 20 Hottest Pipeline Drugs to Watch in 2019

The 20 Hottest Pipeline Drugs to Watch in 2019